ELC-201 is a next-generation oncolytic virus that has been genetically modified to allow the treatment of most cancers. The drug candidate was armed with Elicera’s proprietary platform technology, iTANK, to elicit a parallel immune response and attack on cancer cells by patients’ own endogenous killer T cells. Additionally, ELC-201 is armed with another immune-stimulating factor, 4-1BBL, to further amplify the anti-cancer immune response.
Preclinical studies, including data from animal models of pancreatic cancer, show that ELC-201:
- Effectively infiltrates and kills tumor cells.
- Effectively induces a parallel (bystander) immune response and stimulates the function of tumor-infiltrating immune cells.
- Better controls tumor growth and increases survival compared to placebo.
- Better controls tumor growth and increases survival compared to the same oncolytic virus but without iTANK and 4-1BBL armament.
“ELC-201 represents the cutting edge of research in the field of cell and gene therapies and the conclusion of preclinical proof-of-concept studies represents an important step in bringing the candidate closer to clinical studies. our lead indication for ELC-201,” says
ELC-201 is a next-generation oncolytic virus with three combined modes of action in the treatment of cancer. The drug candidate has been genetically engineered with the company’s proprietary immune enhancement platform technology, iTANK, in addition to 4-1BBL, both of which lead to strong activation of the patient’s endogenous killer T cells, leading to a broad parallel attack on cancer cells. . ELC-201 is applicable for the treatment of most cancers.
About the iTANK platform
The iTANK (immunoTherapies Activated with NAP for efficient Killing) platform is the Company’s fully developed technology platform for enhancing and arming CAR T cells. The technology is used to incorporate a transgene into CAR T cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. Upon activation, NAP was shown to be able to enhance CAR T cell function in addition to activating a parallel immune response via endogenous killer T cells. It is expected to be able to generate a broad attack against most cancer cell targets. The iTANK platform is used to boost the company’s own CAR T cells but can also be applied to other CAR T cells under development. Preclinical proof-of-concept data was recently published in Nature Biomedical Engineering and can be found here: https://www.nature.com/articles/s41551-022-00875-5.
For more information, please contact:
Telephone: +46 (0) 703 31 90 51
For more information, visit www.elicera.com
(c) Decision 2022. All rights reserved., sources